RU2009106089A - Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения - Google Patents

Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения Download PDF

Info

Publication number
RU2009106089A
RU2009106089A RU2009106089/15A RU2009106089A RU2009106089A RU 2009106089 A RU2009106089 A RU 2009106089A RU 2009106089/15 A RU2009106089/15 A RU 2009106089/15A RU 2009106089 A RU2009106089 A RU 2009106089A RU 2009106089 A RU2009106089 A RU 2009106089A
Authority
RU
Russia
Prior art keywords
immunogenic composition
composition according
herv
polypeptide
individual
Prior art date
Application number
RU2009106089/15A
Other languages
English (en)
Russian (ru)
Inventor
Марио ОСТРОВСКИ (CA)
Марио ОСТРОВСКИ
Р. Брэдли ДЖОНС (CA)
Р. Брэдли ДЖОНС
Сет РАКОФФ-НАХОУМ (US)
Сет РАКОФФ-НАХОУМ
Дуглас НИКСОН (US)
Дуглас НИКСОН
Кейт ГАРРИСОН (US)
Кейт ГАРРИСОН
Дункан МЕЙКЛЕДЖОН (US)
Дункан МЕЙКЛЕДЖОН
Эшиш АГРАУОЛ (US)
Эшиш АГРАУОЛ
Джэк ЛЕНЦ (US)
Джэк ЛЕНЦ
Фредерик М. ХЕХТ (US)
Фредерик М. ХЕХТ
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния (Us)
Те Риджентс Оф Те Юниверсити Оф Калифорния
ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС (US)
ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС
Альберт Эйнштейн Коллидж Оф Медсин (Us)
Альберт Эйнштейн Коллидж Оф Медсин
Марио ОСТРОВСКИ (CA)
Марио ОСТРОВСКИ
ДЖОУНЗ Р Брэдли (CA)
ДЖОУНЗ Р Брэдли
Сет РАКОФФ-НАХОУМ (US)
Сет РАКОФФ-НАХОУМ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния (Us), Те Риджентс Оф Те Юниверсити Оф Калифорния, ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС (US), ТЕ Дж. ДЭВИД ГЛЭДСТОУН ИНСТИТЬЮТС, Альберт Эйнштейн Коллидж Оф Медсин (Us), Альберт Эйнштейн Коллидж Оф Медсин, Марио ОСТРОВСКИ (CA), Марио ОСТРОВСКИ, ДЖОУНЗ Р Брэдли (CA), ДЖОУНЗ Р Брэдли, Сет РАКОФФ-НАХОУМ (US), Сет РАКОФФ-НАХОУМ filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния (Us)
Publication of RU2009106089A publication Critical patent/RU2009106089A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2009106089/15A 2006-07-21 2007-07-19 Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения RU2009106089A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
US60/832,465 2006-07-21

Publications (1)

Publication Number Publication Date
RU2009106089A true RU2009106089A (ru) 2010-08-27

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009106089/15A RU2009106089A (ru) 2006-07-21 2007-07-19 Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения

Country Status (15)

Country Link
US (2) US20080171061A1 (enExample)
EP (1) EP2046380A4 (enExample)
JP (1) JP2009544614A (enExample)
KR (1) KR20090060410A (enExample)
CN (1) CN101557823A (enExample)
AU (1) AU2007275693A1 (enExample)
BR (1) BRPI0714714A2 (enExample)
CA (1) CA2658393A1 (enExample)
IL (1) IL196516A0 (enExample)
MX (1) MX2009000659A (enExample)
NO (1) NO20090818L (enExample)
RU (1) RU2009106089A (enExample)
SG (1) SG173997A1 (enExample)
WO (1) WO2008011120A2 (enExample)
ZA (1) ZA200900379B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
JP5504163B2 (ja) * 2008-09-18 2014-05-28 学校法人慶應義塾 がんの診断方法と治療方法
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
EP4502609A3 (en) 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
DK3478711T3 (da) * 2016-06-30 2022-12-12 Us Health Herv-e-reaktive t-cellereceptorer og fremgangsmåder til anvendelse
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ 新規免疫刺激ペプチド
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
JP7457642B2 (ja) * 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
JP7277466B2 (ja) 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および／または治療における使用のためのワクチン
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
US20210330774A1 (en) * 2018-09-06 2021-10-28 Centre Leon Berard Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
US20240189247A1 (en) * 2022-11-16 2024-06-13 The General Hospital Corporation Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
EP1425299A2 (en) * 2001-09-06 2004-06-09 NovImmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
EP1521594B1 (en) * 2001-12-07 2013-10-02 Novartis Vaccines and Diagnostics, Inc. Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Also Published As

Publication number Publication date
EP2046380A2 (en) 2009-04-15
SG173997A1 (en) 2011-09-29
IL196516A0 (en) 2011-08-01
CN101557823A (zh) 2009-10-14
BRPI0714714A2 (pt) 2013-04-09
EP2046380A4 (en) 2013-05-01
MX2009000659A (es) 2009-06-08
US20080171061A1 (en) 2008-07-17
US20130323279A1 (en) 2013-12-05
ZA200900379B (en) 2010-08-25
WO2008011120A3 (en) 2008-11-06
KR20090060410A (ko) 2009-06-12
AU2007275693A1 (en) 2008-01-24
NO20090818L (no) 2009-04-17
CA2658393A1 (en) 2008-01-24
JP2009544614A (ja) 2009-12-17
WO2008011120A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
RU2009106089A (ru) Композиции, содержащие полипептид эндогенного ретровируса человека, и способы их применения
JP2009544614A5 (enExample)
Tomiyama et al. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B* 3501 molecules that are associated with the accelerated progression of AIDS
TW202200199A (zh) 冠狀病毒疫苗及使用方法
RU2721274C2 (ru) Иммуногены для вакцинации против вич
WO2001024810A1 (en) Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CN107011426A (zh) 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
WO2006056027A1 (en) Human cytomegalovirus immunotherapy
EA030741B1 (ru) Адъювантное соединение
US20150250864A1 (en) Anti-cancer vaccines
JP2014207910A (ja) 多価ワクチン
RU2011138160A (ru) Пептиды foxmi и вакцины, содержащие их
RU2009101191A (ru) Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
JP2004508381A (ja) Ｈｉｖペプチド、抗原、ワクチン組成物、ｈｉｖにより誘発される抗体を検出するためのイムノアッセイキット及び方法
EP3466980A2 (en) Improved human herpesvirus immunotherapy
CN115715199A (zh) 冠状病毒疫苗
Suhrbier Polytope vaccines for the codelivery of multiple CD8T-cell epitopes
Ohno et al. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coronavirus-specific cytotoxic T lymphocytes and viral clearance in HLA-A* 0201 transgenic mice
JP2013523084A5 (enExample)
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие
RU2011152975A (ru) Пептиды cdc45l и вакцины, включающие таковые
RU2011140168A (ru) Пептиды vangl1 и содержащие их вакцины
ES2573105T3 (es) Secuencias de péptidos y composiciones
RU2012130015A (ru) Пептиды тмем22 и включающие их вакцины

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120130